By IDSE News Staff
The FDA approved cabotegravir plus rilpivirine (CAB/RPV; Cabenuva, ViiV Healthcare/Janssen), the first long-acting injectable medication for HIV treatment.
CAB/RBV is dosed once monthly as an option to replace a patient’s current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior